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Introduction
The important prerequisite and necessary condition for
successful organ transplantation is effective immunosup-
pressive therapy. New potent immunosuppressive drugs
are available for clinical use today and they dramatically
decrease the number and severity of acute rejection epi-
sodes in the early post-transplant period. Unfortunately,
long-term graft survival is not improved in the same
manner. One possible factor is patient noncompliance,
which emerges as a major problem in modern transplan-
tology, because all regimens have one thing in common –
their effect depends on patients’ willingness to accept the
use of medication and properly follow the treatment.
A variety of explanations has been suggested to des-
cribe the causes and the determinants of noncompliance.
It seems that at least five complex factors play a signifi-
cant role in increased noncompliance: higher prevalence
of side-effects of medication, reduced social support, pre-
transplant noncompliance, low socio-economic status,
and certain psychological and personality characteristics
of the patient (e. g. presence of anxiety, depression, cog-
nitive disorder, the use of avoidant coping strategies).
However, none of these factors seems to lead to absolute
predisposition to noncompliance [1–5].
There is no doubt that major noncompliance is an
important cause of acute rejection episodes and severe
graft damage. Major noncompliance is the situation when
a patient dramatically violates the immunosuppressive
regime with following rejection episode and graft loss as a
consequence. Fortunately major noncompliance is a
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Summary
Noncompliance with therapy is one possible explanation for the observation
that long-term graft survival is not sufficiently improved by the development
in immunosuppression. The aim of the study was to explore the prevalence,
characteristics and risk factors of noncompliance with immunosuppression. A
total of 161 adult kidney transplant recipients were interviewed about their
self-rated health, social support, education, stress from adverse effects and com-
pliance with the immunosuppression. The prevalence of subclinical noncompli-
ance was 54%. Noncompliant patients declared significantly worse self-rated
health, less satisfaction with social support and higher stress from adverse
effects. Male gender (OR 7.5, CI 2.4–23.39), high stress from adverse effects
(OR 12.27, CI 2.44–61.88), fair self-rated health (OR 4.45, CI 1.04–19.55) and
fair satisfaction with social support (OR 4.55, CI 1.08–19.24) were predictors
of noncompliance. Standardized detection methods should be developed with
the aim of identifying patients who are at risk of noncompliance in order to
prevent graft loss.
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patients [6]. Little is known about subclinical noncompli-
ance, which involves violation of treatment assessed in
the absence of any apparent rejection episode or graft
loss. This is a consequence of difficulties with the meas-
urement of subclinical noncompliance, because this phe-
nomenon is hidden and it requires specific instruments
for its detection [3,5,7]. Depending on the detection
method, its prevalence varies between 15% and 53%
[2,7]. Such a wide interval demonstrates that more pre-
cise detection methods are needed for getting a realistic
insight into noncompliance and its clinical consequences.
Subclinical noncompliance is mostly represented by
patients taking lower doses of medication, prolonging
intervals between doses or forgetting to take immunosup-
pressive medication [8–10]. The assessment of subclinical
noncompliance encounters a methodological problem –
there is no golden standard which can be used for its
evaluation. This leads to heterogeneity of results in differ-
ent studies [2,7,10–11]. It seems that electronic monitor-
ing produces the most accurate results, but its use in
daily practice is impossible. So self-reporting in an inter-
view with an independent researcher is often taken as the
measure of choice for use in routine clinical practice
[12,13]. However, even the best interview system always
omits some patients who refuse to declare their noncom-
pliance. This is the reason why in our study we decided
to combine the self-reporting method with the assessment
of noncompliance by a transplant physician who also has
some reliable methods of detection of noncompliance
(e.g. information about cyclosporin A levels, knowledge
about the amount of prescribed immunosuppressive
medication).
Despite the ‘minority’ of subclinical noncompliance in
comparison with major noncompliance, the consequences
are very negative in terms of the final clinical outcome.
The detection of noncompliers is a permanent concern of
the transplant team, because noncompliance is associated
with higher frequency of late graft dysfunction, which is
directly related to graft loss [2,4,14,15]. In addition, non-
compliance is associated with significantly decreased qual-
ity of life [8,16].
The aim of this study was to examine the prevalence of
subclinical noncompliance in kidney transplant recipients
and to explore its characteristics. In addition, the study




Data collection took place between September 2002 and
September 2003 in two transplant centres in the Slovak
Republic (Kosˇice and Bratislava). All adult kidney
transplant recipients with functioning graft, transplanted
more than 3 months and less than 7 years previously,
were informed about the study by their nephrologist.
Patients were not interviewed during any acute disease
requiring hospitalization. Five patients with severe
dementia or mental retardation were excluded. Of the
171 patients, 161 agreed to participate in this study
(response rate 94.1%). Due to incomplete data 22
patients were omitted from the analysis, so the remaining
number of patients was 139 (effective response rate
81.3%). All patients signed an informed consent state-
ment before interview. The study was approved by the
local ethical committee.
Procedures and measures
After literature search [2,7,17] a small pilot study was
performed (n ¼ 11, January 2002). The main aim was to
assess the comprehensibility of selected instruments for
patients. The interview was constructed based on the
results from this pilot study, which included the list of 16
various adverse effects of immunosuppression that can
contribute to noncompliance (Table 1). Stress from each
of these adverse effects of immunosuppression was meas-
ured on a 5-point scale (0, no stress; 1, low stress; 2,
moderate stress; 3, high stress; 4, very high stress). For
each patient a total score of all adverse effects was calcu-
lated as the sum of scores in all items.
Each patient participated in a structured interview with
trained interviewers focused on self-rated health, social
support, education, stress from adverse effects of immu-
nosuppression and compliance with the immunosuppres-
sive therapy.
Self-rated health was assessed on a 5-point scale (1 –
excellent, 2 – good, 3 – average, 4 – fair, 5 – bad) using
the first item from the standardized SF-36 questionnaire.
Satisfaction with social support was measured on a
5-point scale (1 – excellent, 2 – good, 3 – average, 4 –
fair, 5 – bad). Both scales were recoded after preliminary
analysis into 3-point scales due to the low number of
patients in categories 4 and 5, merging the last three cat-
egories together. The scales were changed as follows: 1 –
excellent, 2 – good, 3 – fair. Patients defined their highest
level of education as elementary, secondary or university.
Compliance with the immunosuppression therapy was
measured on a 5-point scale: 1 – excellent, hardly ever
modify the treatment (no more than once per last
month); 2 – good, rarely modify the treatment (two to
three times per last month); 3 – average, sometimes mod-
ify the treatment (once a week); 4 – fair, often modify
the treatment (more than once a week), 5 – bad, always
modify the treatment. Modification of treatment was
explained as missing a dose, prolonging the intervals
Rosenberger et al. Risk of noncompliance
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between doses by more than two hours or changing the
dose of immunosuppressants. The nephrologist was inter-
viewed about each patient’s compliance with the immu-
nosuppression therapy using the same scale as well. No
specific single method was imposed on the nephrologist
to identify noncompliance. Nephrologists mostly based
their opinion on cyclosporin level variations or know-
ledge about prescribed and used immunosuppressants.
Patients were considered to be compliant only if they
declared their compliance by themselves as excellent, in
accord with their physician’s opinion.
Patient medical records were searched for information
about their immunosuppressive regimens, dialysis treat-
ment before transplantation (haemodialysis, peritoneal
dialysis or both methods), graft source (cadaveric, living)
and time from transplantation.
Statistical analyses
Differences between noncompliant and compliant patients
were analysed by t-test or Mann–Whitney U-test for
continuous variables (age, summary score of stress from
immunosuppression, time from transplantation) and chi-
square test or Fisher exact test for categorical variables
(gender, self-rated health, social support, education,
immunosuppressive regimen, dialysis modality before
transplantation). Logistic regression was used to predict
the risk factors of noncompliance. Noncompliance was the
dependent variable; independent variables were the follow-
ing: gender; age (dichotomized into patients younger than
50 years and older); period of transplantation (trichotom-
ized into a group <4 months after transplantation,
patients between 4 and 36 months after transplantation
and those more than 36 months after transplantation);
immunosuppressive protocol; self-rated health; the sum-
mary score of stress from adverse effects, trichotomized
into patients with high stress (score higher than 12; the
fourth quartile), medium stress (score 6–12; the third
quartile) and low stress (score <6; the first and second
quartiles); social support; education; and modality of dia-
lysis before transplantation. Cut-offs for dichotomization
and trichotomization were based on data distribution. Sta-
tistical analyses were performed using SPSS 10.1.0.
Results
A basic description of the patient sample is given in
Table 2 (n ¼ 139). In general the sample consisted of
more men than women (58.1% vs. 41.9%), patients were
of middle age (mean age 47.7 years), they had secondary
education (71.3%) and they were on haemodialysis before
transplantation (79.9%). The majority of organs were
from cadaveric donors (97.5%). The predominant immu-
nosuppression protocol consisted of cyclosporin, myco-
phenolate mofetil (MMF) and prednisone. The mean
serum creatinine was 154.3 ± 63.2 lmol/l.
On average the patients reported good health (self-
rated health mean score 2.01 ± 0.8), a supportive
environment (social support mean score 1.66 ± 0.8) and
relatively low stress from adverse effects (mean summary
score 8.03 ± 6.5; range 0–64). The highest stressors were
malaise, pain, muscle weakness, weight gain, facial chan-
ges, depression and anxiety [18]. Adverse symptoms are
presented in Table 1. Noncompliant patients declared
more stress from all adverse symptoms; the differences
are significant for gingival hyperplasia (P £ 0.001), weight
gain (P £ 0.05) and depression (P £ 0.05).
We asked the patients and their physicians about com-
pliance with the immunosuppressive treatment (Table 3).
During the interview 95 of 139 (68.3%) patients rated
Table 1. Frequency of adverse symp-
toms of immunosuppressive treatment
identified by patients.
Symptom All patients Compliers Noncompliers P-value
Malaise 52.3 46.9 56.4
Pain (headaches, backaches) 51.7 46.9 57.7
Muscle weakness 47.7 37.5 56.4
Weight gain 43.6 36.9 53.6 £0.05
Facial changes (moon face, hirsutism) 40.3 40.6 42.3
Depression 34.2 26.6 42.3 £0.05
Fear, anxiety 33.6 29.7 37.2
Sleep disorders 30.9 25.0 35.9
Gingival hyperplasia 23.5 12.5 32.1 £0.001
Leg oedemas 22.8 17.2 29.5
Skin lesions (eczema, skin tumours, warts) 20.8 12.5 26.9
Hair loss 17.4 17.2 19.2
Facial oedemas 17.4 15.6 19.2
Sexual dysfunction 16.8 12.5 19.2
Diarrhoea 11.4 9.4 14.1
Fragile skin (easy bruises) 10.1 10.9 10.3
Values are expressed as percentage.
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themselves as excellent compliers with their immuno-
suppressive treatment. By contrast, their nephrologist
categorized 82 of 139 (59.0%) as excellent compliers.
When a combination was used for compliance assess-
ment, 64 patients (46.0%) were considered to be compli-
ant and the rest (54.0%) as noncompliant. In one patient
noncompliance was considered to be major, resulting in
graft loss.
Table 4 shows the characteristics of compliant and
noncompliant patients. Noncompliant kidney graft recipi-
ents suffered more from adverse effects of immunosup-
pression (P ¼ 0.003), they experienced worse health
(P ¼ 0.011) and less satisfaction with social support
(P ¼ 0.027). Patients on combination cyclosporin with
MMF were less compliant with the therapy in comparison
with the other protocols (P ¼ 0.049). Compliers did not
differ from noncompliers in other variables.
Risk factors for noncompliant behaviour were exam-
ined using logistic regression (Table 5). Male gender was
associated with 7.5 times greater chance of being non-
compliant when compared with female gender (P ¼
0.001). High stress from adverse effects of immunosup-
pression was a significant risk factor of noncompliance
(P ¼ 0.002). Patients with high stress had 12.3 times
higher probability of being noncompliant in contrast to
those with low stress. However, medium stress was not a
risk factor of noncompliance. Patients with fair self-repor-
ted health had 4.5 times greater chance of being noncom-
pliant in comparison with those with better self-reported
health (P ¼ 0.045). Patients with fair satisfaction with
their social support had 4.5 times increased chance of
noncompliance in comparison with those with better
social support (P ¼ 0.039). None of the other analysed
variables (age, period from transplantation, immunosup-
pressive protocol, education, and modality of dialysis
before transplantation) was identified as a significant risk
factor of noncompliance. The best regression model pre-
sented in Table 5 explained 39.4% variance.
Discussion
Using self-reports, 31.7% of patients rated themselves as
noncompliers; adding the physician’s opinion this number
increased to 54%, which is a more realistic figure than the
wide interval of 15–53% presented in previous studies
[2,7,19–23]. This level of subclinical noncompliance is
quite high compared with previous studies [11], but it is
due to the very strict definition we chose to use. Patients
and their physicians shared the same opinion in 64.7% of
cases (in 64 cases both sides declared full compliance and
in 26 cases noncompliance), while in 35.3% they had dif-
ferent opinions. Combining these two measures together
definitely increased the rate of detection of false noncom-
pliers, although it decreased the number of false compli-
ers, which is of high clinical importance. Their detection
is a prerequisite for possible actions aiming at improving
compliance and therefore reducing the threat of rejection.
The logistic regression analysis of risk factors identified
four significant variables leading to noncompliance in our
sample – male gender (7.5 times higher risk), high stress
from adverse effects of immunosuppression (12.3 times
Table 2. Basic description of the patient sample (n ¼ 139).




Age 47.7 ± 11.7 years (18.3–74)
50 years and less 58.1

















CsA + Aza + P 13.7
CsA + P 15.7
CsA + MMF + P 41.8
Tac + MMF + P 4.6
CsA + MMF 13.1
Aza + CsA 3.9
CsA 7.2
CsA, cyclosporin A; Aza, azathioprine; MMF, mycophenolate mofetil;
Tac, tacrolimus; P, prednisone.




Excellent Good Average Fair Bad
Excellent 64 18 0 0 0
Good 29 16 0 0 0
Average 2 4 1 0 0
Fair 0 4 1 0 0
Bad 0 0 0 0 0
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higher risk), worse self-rated health (4.5 times higher risk)
and fair satisfaction with social support (4.5 times higher
risk). There exists some diversity in findings of risk fac-
tors of noncompliance among various studies depending
on the method of compliance assessment, statistical analy-
sis and the composition of studied samples. The majority
of studies found younger age as a significant risk factor
[20–24]. However, paediatric patients were included in
these studies in contrast to our research, where only 10%
of included patients were of age younger than 30 years.
Frazier et al. [24] demonstrated that female gender and
marital status is connected with noncompliant behaviour
from self-reports of 241 kidney transplant recipients. In
their analysis, transplant-related stress was revealed as the
strongest predictor of noncompliance, explaining 12%
variance, and gender and marital status together accounted
for only 8% of explained variance. In contrast, Kiley et al.
[25] found, among 105 renal allograft recipients, that male
gender was associated with noncompliance with the medi-
cation. These results are in concordance with our findings,
although their definition of noncompliance was based on
cyclosporin levels and the statistical approach was quite
different from ours. Other studies did not show gender to
be a risk factor of noncompliance; their definitions of non-
compliance were based on self-reports from mailed ques-
tionnaires [22,23]. These results are in accordance with
previous research regarding gender differences in health –
females usually report worse health indicators despite their
mortality and morbidity being lower than in the male
population. According to Gijsbers van Wijk and Kolk,
females perceive health problems more precisely and accu-
rately than males, who are inclined to deny them [26].
Patients with low socio-economic status were found to
be at risk of becoming noncompliant in six studies
Table 4. Differences between compliant
and noncompliant patients.Compliant Noncompliant P-value
Variables in v2-test (frequency)
Gender
Male 34 53 0.071
Female 30 25
Current immunosuppressive regimen
CsA, azathioprine, prednisone 12 8 0.111
CsA, prednisone 9 15 0.283
CsA, MMF, prednisone 26 29 0.734
Tacrolimus, MMF, prednisone 4 3 0.388
CsA, MMF 3 13 0.049*
Azathioprine, CsA 3 3 0.751
CsA 4 5 0.627
Self-rated health
Excellent 24 13 0.011*
Good 30 41
Fair 10 23
Satisfaction with social support




Elementary 6 9 0.682
Secondary 47 52
University 11 17
Dialysis modality before transplantation
Haemodialysis 53 59 0.570
Peritoneal dialysis 8 10
Both methods 3 7
Variables in t-test (mean ± SD)
Age 46.5 ± 11.4 49.4 ± 11.9 0.149
Serum creatinine 158.7 ± 72.1 153.1 ± 60.9 0.675
Time from transplantation 41.2 ± 27.7 37.2 ± 26.5 0.384
Total score of stress from adverse effects 6.4 ± 4.9 9.7 ± 7.5 0.003**
*P < 0.05, **P < 0.01.
Fisher’s exact test.
Mann–Whitney U-test.
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[20,22–25,27]. This variable was partially assessed in our
study, and we used education as an indicator, although
we still did not find it to be a risk factor for noncompli-
ance. One possible explanation for this fact can be that all
immunosuppressive medication as well as erythropoetin
is fully covered by the compulsory health insurance in
Slovakia and every patient receives it free of charge. Other
drugs (antihypertensives, diuretics, vitamin supplements,
etc.) are partially covered by the health insurance and
patients have to pay approximately 2–13€ per month for
this additional medication. Secondly, our sample con-
tained only 15 patients with elementary education and
such a low number of people at possible risk could affect
the results as well. We found high stress from adverse
effects to be a very important risk factor of noncompli-
ance, similar to studies by De Geest et al. [2], Frazier
et al. [24] and Raiz et al. [22]. Some studies found psy-
chological factors, including depression, anxiety, patient’s
beliefs and coping strategies, to be predictors of noncom-
pliance [4,28,29]. These variables were not assessed in our
study and one might expect them to be behind the unex-
plained variance of noncompliance. These factors require
a study with use of valid and reliable instruments to
assess their possible influence on patients’ compliance.
However, adding more psychological questionnaires could
decrease the cooperation of patients and lower their
response rate, so we decided not to evaluate them.
Another possible predictor which was not evaluated in
our study was pretransplant noncompliance, which can
be (validly) measured only before transplantation. The
design of our study was cross-sectional and the recruited
patients were questioned at various times after transplan-
tation (3 months–7 years). Measurement of pretransplant
noncompliance retrospectively in such a study might pro-
duce questionable results.
The results of the present study also demonstrate that
self-rated health affects compliance. Previously this
parameter was known to be a predictor of morbidity and
mortality [1,30], but it seems that it plays a crucial role
in patients’ adherence to the therapy as well. This means
that self-rated health can be used as a cheap and easily
measurable predictor of noncompliance in routine clinical
practice.
In accord with previous research, social support was
found to be an important predictor of noncompliance
[2]. While some researchers use marital status as a proxy
of social support, others prefer complex validated ques-
tionnaires. In our study we decided to ask about satisfac-
tion with patients’ social support, which seems to be
more appropriate.
Despite nonsignificant differences in serum creatinine
between compliers and noncompliers, we do not think
that noncompliance is without influence on graft function
[2,4,6,11,14,19]. Our research had cross-sectional design
and therefore selection bias is present. We only evaluated
patients with functional graft, and those with graft failure
(e.g. due to noncompliance) were not invited. For assess-
ment of the influence of noncompliance on graft survival
or graft function longitudinal research is needed.
Our findings show that subclinical noncompliance is a
quite common situation, appearing in more than half of
our patients. The detection of this feature is of important
clinical interest and the investigation techniques require
constant updates [13]. It seems reasonable to increase the
rate of detection of noncompliers by adding the physi-
cian’s opinion to the patient’s self-referral.
The presented regression model predicted noncompli-
ance in 70 patients, 20 of them were observed as com-
pliers (71.4% were correctly classified). We may expect
these 20 patients to become noncompliers. From a
practical point of view, identification of patients at risk
of becoming noncompliant is necessary. With the help
of prediction models we might be able to detect sub-
clinical noncompliers (approximately 15% of all
patients). Based on these results we suggest the policy
of assessing compliance and its predictors at the third
and twelfth months after transplantation and each year
thereafter.
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Male gender 0.001** 7.49 2.40–23.39
Immunosuppressive protocol
CsA, azathioprine, prednisone 0.066 3.22 0.93–11.17
CsA, MMF 0.057 0.24 0.057–1.05
Self-rated health
Fair 0.045* 4.50 1.04–19.55
Good 0.067 2.96 0.93–9.44
Summary score of stress from adverse effects




Satisfaction with social support
Fair 0.039* 4.55 1.08–19.24
Good 0.745 0.85 0.32–2.25
Education
Elementary 0.214 3.01 0.53–17.09




*P < 0.05, **P < 0.01.
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